Patrys Quarterly Activities Report and Appendix 4CMelbourne,...

Patrys Quarterly Activities Report and Appendix 4C
Melbourne, Australia; 30 July 2020: Patrys (ASX: PAB, “Patrys” or the Company), a therapeutic
antibody development company, is pleased to announce further progress across its Deoxymab
platform (including PAT-DX1 and PAT-DX1-NP) and the release of its Appendix 4C for the quarter
ended 30 June 2020.
Key highlights
• Appointment of Dr. Peter Ordentlich to Scientific Advisory Board to strengthen skill base
as Patrys moves towards anticipated Phase 1 study
• Patrys collaborators have been awarded Lion Heart Fund for Cancer Research grant of
US$50,000; US National Institutes of Health (NIH) R01 grant of US$1.83m; and Department
of Defence (DoD) grant of US$1.95m, to support ongoing work in the areas of glioblastoma
(GBM) and breast cancer metastases
• Announcement of fully underwritten, non-renounceable rights issue to raise
approximately A$4.29 million before costs supported by two of Patrys’ largest
shareholders
• Cash at bank at close of quarter of A$3.98m and net cash outflows of A$619k including
A$411k invested in R&D activities
Operations